Pharmacist Interventions for Medication Adherence: Community Guide Economic Reviews for Cardiovascular Disease.

Cardiovascular Diseases / drug therapy Cost-Benefit Analysis Humans Medication Adherence Pharmacists Quality-Adjusted Life Years

Journal

American journal of preventive medicine
ISSN: 1873-2607
Titre abrégé: Am J Prev Med
Pays: Netherlands
ID NLM: 8704773

Informations de publication

Date de publication:
03 2022
Historique:
received: 28 05 2021
revised: 26 08 2021
accepted: 27 08 2021
pubmed: 9 12 2021
medline: 1 4 2022
entrez: 8 12 2021
Statut: ppublish

Résumé

Adherence to medications for cardiovascular disease and its risk factors is less than optimal, although greater adherence to medication has been shown to reduce the risk factors for cardiovascular disease. This paper examines the economics of tailored pharmacy interventions to improve medication adherence for cardiovascular disease prevention and management. Literature from inception of databases to May 2019 was searched, yielding 29 studies for cardiovascular disease prevention and 9 studies for cardiovascular disease management. Analyses were done from June 2019 through May 2020. All monetary values are in 2019 U.S. dollars. The median intervention cost per patient per year was $246 for cardiovascular disease prevention and $292 for cardiovascular disease management. The median change in healthcare cost per person per year due to the intervention was -$355 for cardiovascular disease prevention and -$2,430 for cardiovascular disease management. The median total cost per person per year was -$89 for cardiovascular disease prevention, with a median return on investment of 0.01. The median total cost per person per year for cardiovascular disease management was -$1,080, with a median return on investment of 7.52, and 6 of 7 estimates indicating reduced healthcare cost averted exceeded intervention cost. For cardiovascular disease prevention, the median cost per quality-adjusted life year gained was $11,298. There were no cost effectiveness studies for cardiovascular disease management. The evidence shows that tailored pharmacy-based interventions to improve medication adherence are cost effective for cardiovascular disease prevention. For cardiovascular disease management, healthcare cost averted exceeds the cost of implementation for a favorable return on investment from a healthcare systems perspective.

Identifiants

DOI: 10.1016/j.amepre.2021.08.021 PMID: 34876318 PMC: PMC8863641
pubmed: 34876318
pii: S0749-3797(21)00507-9
doi: 10.1016/j.amepre.2021.08.021
pmc: PMC8863641
mid: NIHMS1768637
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202-e222

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Références

Farm Hosp. 2006 Nov-Dec;30(6):328-42
pubmed: 17298190
Prog Cardiovasc Dis. 2021 Jan-Feb;64:111-120
pubmed: 32800791
J Am Pharm Assoc (2003). 2019 Mar - Apr;59(2):285-290
pubmed: 30611660
J Manag Care Pharm. 2010 Apr;16(3):185-95
pubmed: 20331323
Evid Rep Technol Assess (Full Rep). 2012 Sep;(208.4):1-685
pubmed: 24422970
Health Aff (Millwood). 2014 Aug;33(8):1444-52
pubmed: 25092847
Pharmacotherapy. 2000 Dec;20(12):1508-16
pubmed: 11130223
Stroke. 2010 Feb;41(2):397-401
pubmed: 20075360
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
J Am Pharm Assoc (2003). 2016 Jul-Aug;56(4):389-96
pubmed: 27184784
Am J Kidney Dis. 2012 Nov;60(5):850-86
pubmed: 23067652
Value Health. 2004 Sep-Oct;7(5):518-28
pubmed: 15367247
Health Aff (Millwood). 2011 Jan;30(1):91-9
pubmed: 21209444
Int J Clin Pharm. 2016 Feb;38(1):88-95
pubmed: 26499503
J Am Heart Assoc. 2019 Nov 19;8(22):e013627
pubmed: 31711390
J Cardiovasc Pharmacol Ther. 2011 Mar;16(1):43-52
pubmed: 20924095
Ann Intern Med. 2007 May 15;146(10):714-25
pubmed: 17502632
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Manag Care. 2012 Mar;21(3):44-54
pubmed: 22471165
Am J Kidney Dis. 2000 Sep;36(3):646-61
pubmed: 10977801
Am J Manag Care. 2014 Mar 01;20(3):e72-81
pubmed: 24773329
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Can J Cardiol. 2017 Feb;33(2):219-231
pubmed: 27956043
N Engl J Med. 2001 Sep 20;345(12):851-60
pubmed: 11565517
Eur Heart J. 2013 Oct;34(38):2933-9
pubmed: 23861328
J Pharm Pract. 2012 Apr;25(2):169-79
pubmed: 21987530
Pharmacotherapy. 1997 Nov-Dec;17(6):1274-85
pubmed: 9399611
J Am Soc Nephrol. 2013 Feb;24(2):302-8
pubmed: 23362314
J Manag Care Pharm. 2008 Nov-Dec;14(9):831-43
pubmed: 19006440
Pharmacoeconomics. 2003;21(6):415-28
pubmed: 12678568
Pharm Pract (Granada). 2009 Apr;7(2):94-9
pubmed: 25152784
Am J Manag Care. 2001 Oct;7(10):973-9
pubmed: 11669361
N Engl J Med. 2001 Sep 20;345(12):861-9
pubmed: 11565518
Pharmacoeconomics. 2007;25(5):397-411
pubmed: 17488138
Front Pharmacol. 2019 Mar 07;10:210
pubmed: 30899223
J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):23-31
pubmed: 18192127
Am J Med. 2012 Sep;125(9):882-7.e1
pubmed: 22748400
Med Care. 2012 Nov;50(11):997-1001
pubmed: 23047790
Hypertension. 2020 Jun;75(6):1334-1357
pubmed: 32370572
Can Pharm J (Ott). 2014 Jul;147(4):209-32
pubmed: 25360148
Pharmacotherapy. 2003 Feb;23(2):209-16
pubmed: 12587810
Trends Cardiovasc Med. 2020 Apr;30(3):160-164
pubmed: 31521481
Diabetes Care. 2020 Jan;43(Suppl 1):S135-S151
pubmed: 31862754
J Am Pharm Assoc (Wash). 2003 Mar-Apr;43(2):173-84
pubmed: 12688435
Prev Chronic Dis. 2019 Nov 21;16:E153
pubmed: 31753083
J Manag Care Pharm. 2013 Apr;19(3):228-36
pubmed: 23537457
Res Social Adm Pharm. 2019 Jan;15(1):84-92
pubmed: 29610052
J Hypertens. 2017 Jan;35(1):178-187
pubmed: 27684354
BMJ Open. 2018 Jan 21;8(1):e016982
pubmed: 29358417
J Manag Care Spec Pharm. 2014 Oct;20(10):1036-45
pubmed: 25278326
J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):57-64
pubmed: 21335480
Integr Pharm Res Pract. 2019 Feb 04;8:1-11
pubmed: 30788283
BMC Cardiovasc Disord. 2006 Dec 15;6:48
pubmed: 17173679
Pharmacotherapy. 2008 Apr;28(4):437-43
pubmed: 18363527
Diabetologia. 2011 Jan;54(1):32-43
pubmed: 20668832
Circulation. 2018 Aug 28;138(9):929-944
pubmed: 30354446
J Card Fail. 2004 Dec;10(6):473-80
pubmed: 15599837
J Manag Care Spec Pharm. 2014 Jul;20(7):722-32
pubmed: 24967525
Am Fam Physician. 2019 May 1;99(9):589-591
pubmed: 31038893
Health Aff (Millwood). 2016 Jul 1;35(7):1222-9
pubmed: 27385237
J Manag Care Pharm. 2013 Mar;19(2):102-14
pubmed: 23461426
J Am Coll Clin Pharm. 2018 Oct;1(1):21-30
pubmed: 30320302
Am J Manag Care. 2013 Sep;19(9):709-16
pubmed: 24304254
Pharmacotherapy. 2010 Nov;30(11):1127-35
pubmed: 20973686
J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232
pubmed: 30894318
J Am Pharm Assoc (2003). 2007 Jul-Aug;47(4):471-83
pubmed: 17616493
J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414
pubmed: 30894319

Auteurs

Verughese Jacob (V)

The Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: hir0@cdc.gov.

Jeffrey A Reynolds (JA)

The Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia; Cherokee Nation Assurance LLC, Catoosa, Oklahoma.

Sajal K Chattopadhyay (SK)

The Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

David P Hopkins (DP)

The Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia.

Nicole L Therrien (NL)

ASRT, Inc., Smyrna, Georgia; Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

Christopher D Jones (CD)

Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

Jeffrey M Durthaler (JM)

Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

Kimberly J Rask (KJ)

Alliant Health Solutions, Atlanta, Georgia.

Alison E Cuellar (AE)

Department of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, Virginia.

John M Clymer (JM)

National Forum for Heart Disease & Stroke Prevention, Washington, District of Columbia.

Thomas E Kottke (TE)

HealthPartners Institute, Bloomington, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies cardiovasculaires › Pharmacist Interventions for Medication...
questionsmedicales.fr › Organisations et économie des soins de santé › Économie › Coûts et analyse des coûts › Analyse coût-bénéfice › Pharmacist Interventions for Medication...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pharmacist Interventions for Medication...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Attitude envers la santé › Adhésion et observance thérapeutiques › Acceptation des soins par les patients › Observance par le patient › Adhésion au traitement médicamenteux › Pharmacist Interventions for Medication...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Pharmaciens › Pharmacist Interventions for Medication...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Espérance de vie › Années de vie ajustées sur la qualité › Pharmacist Interventions for Medication...